Cargando…
Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AGA Institute. Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212464/ http://dx.doi.org/10.1016/S0016-5085(22)61407-0 |
| _version_ | 1784730599904247808 |
|---|---|
| author | Alexander, James L. Kennedy, Nick Ibraheim, Hajir Anandabaskaran, Sulak Saifuddin, Aamir Seoane, Rocio Castro Liu, Zhigang Nice, Rachel Bewshea, Claire M. D'Mello, Andrea Constable, Laura E. Jones, Gareth-Rhys Balarajah, Sharmili Fiorentino, Francesca Sebastian, Shaji Irving, Peter M. Hicks, Lucy C. Williams, Horace R. Kent, Alexandra J. Parkes, Miles Kok, Klaartje Patel, Kamal V Altmann, Daniel Boyton, Rosemary Goodhand, James Hart, Ailsa Lees, Charlie W. Ahmad, Tariq Powell, Nick |
| author_facet | Alexander, James L. Kennedy, Nick Ibraheim, Hajir Anandabaskaran, Sulak Saifuddin, Aamir Seoane, Rocio Castro Liu, Zhigang Nice, Rachel Bewshea, Claire M. D'Mello, Andrea Constable, Laura E. Jones, Gareth-Rhys Balarajah, Sharmili Fiorentino, Francesca Sebastian, Shaji Irving, Peter M. Hicks, Lucy C. Williams, Horace R. Kent, Alexandra J. Parkes, Miles Kok, Klaartje Patel, Kamal V Altmann, Daniel Boyton, Rosemary Goodhand, James Hart, Ailsa Lees, Charlie W. Ahmad, Tariq Powell, Nick |
| author_sort | Alexander, James L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9212464 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | AGA Institute. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92124642022-06-22 Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB Alexander, James L. Kennedy, Nick Ibraheim, Hajir Anandabaskaran, Sulak Saifuddin, Aamir Seoane, Rocio Castro Liu, Zhigang Nice, Rachel Bewshea, Claire M. D'Mello, Andrea Constable, Laura E. Jones, Gareth-Rhys Balarajah, Sharmili Fiorentino, Francesca Sebastian, Shaji Irving, Peter M. Hicks, Lucy C. Williams, Horace R. Kent, Alexandra J. Parkes, Miles Kok, Klaartje Patel, Kamal V Altmann, Daniel Boyton, Rosemary Goodhand, James Hart, Ailsa Lees, Charlie W. Ahmad, Tariq Powell, Nick Gastroenterology AGA Abstracts AGA Institute. Published by Elsevier Inc. 2022-05 2022-06-16 /pmc/articles/PMC9212464/ http://dx.doi.org/10.1016/S0016-5085(22)61407-0 Text en Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | AGA Abstracts Alexander, James L. Kennedy, Nick Ibraheim, Hajir Anandabaskaran, Sulak Saifuddin, Aamir Seoane, Rocio Castro Liu, Zhigang Nice, Rachel Bewshea, Claire M. D'Mello, Andrea Constable, Laura E. Jones, Gareth-Rhys Balarajah, Sharmili Fiorentino, Francesca Sebastian, Shaji Irving, Peter M. Hicks, Lucy C. Williams, Horace R. Kent, Alexandra J. Parkes, Miles Kok, Klaartje Patel, Kamal V Altmann, Daniel Boyton, Rosemary Goodhand, James Hart, Ailsa Lees, Charlie W. Ahmad, Tariq Powell, Nick Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB |
| title | Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB |
| title_full | Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB |
| title_fullStr | Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB |
| title_full_unstemmed | Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB |
| title_short | Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB |
| title_sort | su1485: covid-19 vaccine-induced antibody responses are impaired in ibd patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab |
| topic | AGA Abstracts |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212464/ http://dx.doi.org/10.1016/S0016-5085(22)61407-0 |
| work_keys_str_mv | AT alexanderjamesl su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT kennedynick su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT ibraheimhajir su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT anandabaskaransulak su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT saifuddinaamir su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT seoanerociocastro su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT liuzhigang su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT nicerachel su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT bewsheaclairem su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT dmelloandrea su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT constablelaurae su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT jonesgarethrhys su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT balarajahsharmili su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT fiorentinofrancesca su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT sebastianshaji su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT irvingpeterm su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT hickslucyc su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT williamshoracer su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT kentalexandraj su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT parkesmiles su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT kokklaartje su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT patelkamalv su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT altmanndaniel su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT boytonrosemary su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT goodhandjames su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT hartailsa su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT leescharliew su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT ahmadtariq su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab AT powellnick su1485covid19vaccineinducedantibodyresponsesareimpairedinibdpatientstreatedwithinfliximabustekinumabortofacitinibbutnotthiopurinesorvedolizumab |